E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients experiencing an alcohol withdrawal syndrome. |
NA |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Behaviours [F01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10053164 |
E.1.2 | Term | Alcohol withdrawal syndrome |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To examine the efficacy of oral magnesium supplementation as an adjuvant therapy for decreasing intensity of AWS among inpatients requiring pharmacological treatment of their AWS. |
NA |
|
E.2.2 | Secondary objectives of the trial |
1 To examine whether oral magnesium supplementation as an adjuvant drug therapy for AWS: a Reduces benzodiazepine consumption; b Reduces the length of the withdrawal syndrome; c Reduces incidence of seizure and delirium tremens during withdrawal syndrome; d Reduces intensity of withdrawal symptoms in patients with severe physical comorbidities; e Reduces intensity of withdrawal symptoms in elderly patients (i.e. from 60 to 75 years); f Decreases the risk of leaving the hospital before the end of care; g Helps patients to enroll in a weaning process; h Increases patient satisfaction; i Is associated with changes in plasmatic magnesium concentration; j Induces adverse effects;
|
NA |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria: Patients eligible for inclusion in this study have to fulfill all the following criteria: - Adult inpatients, men and women (i.e. age>18 years and <75 years) ; - Current AWS according to DSM-5 criteria; - Score at the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) >8; - Written informed consent to participate in the study. - Affiliation to the French Social Security Health Care plan
|
NA |
|
E.4 | Principal exclusion criteria |
Non-inclusion criteria - Age less than 18 or greater than 75; - Hemodynamic failure; - Arythmia; - Lack of fulfilling AWS criteria according to DSM-5; - Score at the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) <=8; - Other current substance use disorder regarding DSM-5 criteria, including benzodiazepine substance use disorder and except for tobacco. In addition to benzodiazepine substance use disorder, following criteria of inappropriate use of benzodiazepine and related-benzodiazepine hypnotics are also considered as non-inclusion criteria: - over-the-counter consumption; - consumption outside the indications of marketing authorization; - excessive dosage or duration regarding guidelines. Licit or illicit substance consumption that is not fulfilling substance use disorder DSM-5 criteria is not considered as a non-inclusion criterion (e.g. cannabis consumption without sufficient criteria to diagnose substance use disorder regarding DSM-5 criteria); - Pregnancy or breast-feeding; - Unable to take oral medications; - Creatinine clearance <30mL/min according to the Cockcroft-Gault Equation; - Cognitive disorders that impair the informed consent, including dementia (except for acute withdrawal delirium); - Psychiatric disorder requiring hospitalization or specific cares in emergency (e.g. suicidal crisis, acute psychotic episode); - Magnesium supplementation (regardless the type of delivery) within 3 months prior to inclusion; - Actual quinidine intake; - No written informed consent to participate in the study.
|
NA |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: The primary endpoint is the between-group absolute difference of the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) score change from baseline, 3 days after randomization. Secondary endpoints: a Total benzodiazepine consumption compared between experimental and control groups throughout the duration of the study (i.e. 15 days); b Time required to obtain a total score of 0 at the CIWA-Ar compared between experimental and control groups; c Rate of patients experiencing seizures and delirium tremens during the study compared between intervention and control groups; d Stratify results of the Primary endpoint following score at the Charlson Comorbidity Index; e Stratify results of the Primary endpoint by age; f Number of participants who left the hospital against medical advice during the study compared between experimental and control groups; g Number of participants who made an appointment in an addiction unit during the study (i.e. before the last follow-up point, 15 days after baseline), compared between experimental and control groups after stratification following AUD duration and number of previous addiction healthcare; h Patient Satisfaction Questionnaire-18 (PSQ-18) scores at the last follow-up point (i.e. days after baseline) compared between experimental and control groups; i Total plasmatic magnesium concentration changes between baseline, 3 days after baseline, and 7 days after baseline; j Rate of all adverse events occurred during the study incidence compared between experimental and control groups;
|
NA |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
a Total benzodiazepine consumption compared between experimental and control groups throughout the duration of the study (i.e. 15 days); b Time required to obtain a total score of 0 at the CIWA-Ar compared between experimental and control groups; c Rate of patients experiencing seizures and delirium tremens during the study compared between intervention and control groups; d Stratify results of the Primary endpoint following score at the Charlson Comorbidity Index; e Stratify results of the Primary endpoint by age; f Number of participants who left the hospital against medical advice during the study compared between experimental and control groups; g Number of participants who made an appointment in an addiction unit during the study (i.e. before the last follow-up point, 15 days after baseline), compared between experimental and control groups after stratification following AUD duration and number of previous addiction healthcare; h Patient Satisfaction Questionnaire-18 (PSQ-18) scores at the last follow-up point (i.e. days after baseline) compared between experimental and control groups; i Total plasmatic magnesium concentration changes between baseline, 3 days after baseline, and 7 days after baseline; j Rate of all adverse events occurred during the study incidence compared between experimental and control groups; |
NA |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.6.13.1 | Other scope of the trial description |
Patients experiencing an alcohol withdrawal syndrome. |
Patients souffrant de syndrome de sevrage alcoolique. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |